- Home
- ALNY
as of 01-02-2026 3:49pm EST
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 52.9B | IPO Year: | 2004 |
| Target Price: | $479.45 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 28 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $205.87 - $495.55 | Next Earning Date: | 02-12-2026 |
| Revenue: | $3,210,070,000 | Revenue Growth: | 53.24% |
| Revenue Growth (this year): | 70.04% | Revenue Growth (next year): | 43.08% |
AI-Powered ALNY Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)
CSO & EVP, Head of Research
Avg Cost/Share
$456.70
Shares
12,128
Total Value
$5,483,989.61
Owned After
21,264
Chief Executive Officer
Avg Cost/Share
$451.86
Shares
10,000
Total Value
$4,512,681.86
Owned After
68,345
Chief Executive Officer
Avg Cost/Share
$453.42
Shares
15,650
Total Value
$7,100,321.56
Owned After
68,345
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Nov 17, 2025 | Sell | $456.70 | 12,128 | $5,483,989.61 | 21,264 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Nov 13, 2025 | Sell | $451.86 | 10,000 | $4,512,681.86 | 68,345 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Nov 12, 2025 | Sell | $453.42 | 15,650 | $7,100,321.56 | 68,345 |
Compare ALNY vs Leading Stocks
See how ALNY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALNY Alnylam Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.